Healthy men help scientists track how a new drug leaves the body
NCT ID NCT04771286
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study looked at how healthy men absorb, break down, and eliminate a single dose of the drug BI 1015550 (Nerandomilast). Six participants provided urine and stool samples over several days to measure how much of the drug and its byproducts leave the body. The goal was purely to understand the drug's metabolism and excretion, not to test any treatment effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 1015550 (also called Nerandomilast or JASCAYD®)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test